期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 9, 期 3, 页码 274-U111出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2010.11.040
关键词
Entecavir; Biopsy; Ishak Fibrosis Score; Histologic Improvement
资金
- Bristol-Myers Squibb Company
- Abbott
- Anadys
- Gilead
- GlobeImmune Inc
- Merck
- Medtronics
- Roche Diagnostics
- Roche Molecular
- Salix Pharmaceuticals Inc
- Sanofi Aventis
- Schering-Plough
- Sciclone
- Vertex Pharmaceuticals
- Bristol-Myers Squibb
BACKGROUND & AIMS: Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. Patients with advanced fibrosis or cirrhosis, who received long-term entecavir treatment, were evaluated for improvement in liver histology. METHODS: The study included a subset of patients from phase III and long-term roll-over studies, who received entecavir for at least 3 years, had advanced fibrosis or cirrhosis, and evaluable biopsies at baseline and after long-term treatment. RESULTS: Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score, >= 4). After approximately 6 years of cumulative entecavir therapy (range, 267-297 wk), all 10 patients showed improvement in liver histology and Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and Knodell necroinflammatory scores were -2.2 and -7.6, respectively. A reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients who had cirrhosis at baseline. CONCLUSIONS: Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated histologic improvement and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据